Nausea: Experienced by 4261% of patients, nausea is the leading cause of treatment discontinuation
Conclusion (Summary first) GLP-1 receptor agonists may increase the risk of cholelithiasis and gallbladder disease The risk is tending to be higher with drugs and dosages that cause greater weight loss The mechanism is reduced gallbladder motility + rapid weight loss Cholelithiasis risk: Overall picture In large-scale meta-analyses, GLP-1 receptor agonist use Gallbladder disease risk: RR 1.37 Cholelithiasis: RR 1.27 Cholecystitis: RR 1.36 1) It is important to note that while this is a significant increase, the "absolute risk is not high." Differences in risk by drug Liraglutide (Victoza) The increase in cholelithiasis risk is relatively clear In the SCALE trials, Gallstone-related events: 2.3% vs 1.0% (placebo) 2) Increased in the group with greater weight loss Semaglutide (Ozempic/Wegovy) In the STEP trials, etc., Gallbladder disease increasing trend (approx
L-Carnitine is a naturally occurring amino acid-like compound produced in the body from lysine and methionine
I just remember everyone telling me GLP-1s, or taking the Ozempic or the Mounjaro, Listen, its gonna hurt your stomach a little bit,' Jelly Roll, 41, shared in a new Mens Health profile published on Friday, January 2
Erythropoietin mitigates diabetic nephropathy by restoring PINK1/Parkin-Mediated mitophagy
